Lexicon Pharmaceuticals Competitors

Lexicon Pharmaceuticals (NASDAQ:LXRX) and Amgen (NASDAQ:AMGN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, dividends and valuation.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Lexicon Pharmaceuticals and Amgen, as provided by MarketBeat.com.

Lexicon Pharmaceuticals currently has a consensus price target of $9.40, suggesting a potential upside of 75.05%. Amgen has a consensus price target of $259.4091, suggesting a potential upside of 4.20%. Given Lexicon Pharmaceuticals' higher possible upside, analysts plainly believe Lexicon Pharmaceuticals is more favorable than Amgen.

Volatility and Risk

Lexicon Pharmaceuticals has a beta of 2.09, indicating that its share price is 109% more volatile than the S&P 500. Comparatively, Amgen has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500.

Earnings and Valuation

This table compares Lexicon Pharmaceuticals and Amgen's top-line revenue, earnings per share and valuation.

Amgen has higher revenue and earnings than Lexicon Pharmaceuticals. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Lexicon Pharmaceuticals and Amgen's net margins, return on equity and return on assets.

Insider & Institutional Ownership

84.6% of Lexicon Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.2% of Amgen shares are owned by institutional investors. 6.4% of Lexicon Pharmaceuticals shares are owned by insiders. Comparatively, 0.4% of Amgen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Amgen beats Lexicon Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

Lexicon Pharmaceuticals (NASDAQ:LXRX) and Gilead Sciences (NASDAQ:GILD) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, dividends and valuation.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Lexicon Pharmaceuticals and Gilead Sciences, as provided by MarketBeat.com.

Lexicon Pharmaceuticals currently has a consensus price target of $9.40, suggesting a potential upside of 75.05%. Gilead Sciences has a consensus price target of $97.2308, suggesting a potential upside of 49.33%. Given Lexicon Pharmaceuticals' higher possible upside, analysts plainly believe Lexicon Pharmaceuticals is more favorable than Gilead Sciences.

Volatility and Risk

Lexicon Pharmaceuticals has a beta of 2.09, indicating that its share price is 109% more volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500.

Earnings and Valuation

This table compares Lexicon Pharmaceuticals and Gilead Sciences' top-line revenue, earnings per share and valuation.

Gilead Sciences has higher revenue and earnings than Lexicon Pharmaceuticals. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Lexicon Pharmaceuticals and Gilead Sciences' net margins, return on equity and return on assets.

Insider & Institutional Ownership

84.6% of Lexicon Pharmaceuticals shares are owned by institutional investors. Comparatively, 76.4% of Gilead Sciences shares are owned by institutional investors. 6.4% of Lexicon Pharmaceuticals shares are owned by insiders. Comparatively, 0.1% of Gilead Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Gilead Sciences beats Lexicon Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

Lexicon Pharmaceuticals (NASDAQ:LXRX) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, dividends and valuation.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Lexicon Pharmaceuticals and Vertex Pharmaceuticals, as provided by MarketBeat.com.

Lexicon Pharmaceuticals currently has a consensus price target of $9.40, suggesting a potential upside of 75.05%. Vertex Pharmaceuticals has a consensus price target of $293.1250, suggesting a potential upside of 37.39%. Given Lexicon Pharmaceuticals' higher possible upside, analysts plainly believe Lexicon Pharmaceuticals is more favorable than Vertex Pharmaceuticals.

Volatility and Risk

Lexicon Pharmaceuticals has a beta of 2.09, indicating that its share price is 109% more volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500.

Earnings and Valuation

This table compares Lexicon Pharmaceuticals and Vertex Pharmaceuticals' top-line revenue, earnings per share and valuation.

Vertex Pharmaceuticals has higher revenue and earnings than Lexicon Pharmaceuticals. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Lexicon Pharmaceuticals and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Insider & Institutional Ownership

84.6% of Lexicon Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.2% of Vertex Pharmaceuticals shares are owned by institutional investors. 6.4% of Lexicon Pharmaceuticals shares are owned by insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Vertex Pharmaceuticals beats Lexicon Pharmaceuticals on 12 of the 15 factors compared between the two stocks.

Lexicon Pharmaceuticals (NASDAQ:LXRX) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, dividends and valuation.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Lexicon Pharmaceuticals and Regeneron Pharmaceuticals, as provided by MarketBeat.com.

Lexicon Pharmaceuticals currently has a consensus price target of $9.40, suggesting a potential upside of 75.05%. Regeneron Pharmaceuticals has a consensus price target of $637.2083, suggesting a potential upside of 34.10%. Given Lexicon Pharmaceuticals' higher possible upside, analysts plainly believe Lexicon Pharmaceuticals is more favorable than Regeneron Pharmaceuticals.

Volatility and Risk

Lexicon Pharmaceuticals has a beta of 2.09, indicating that its share price is 109% more volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500.

Earnings and Valuation

This table compares Lexicon Pharmaceuticals and Regeneron Pharmaceuticals' top-line revenue, earnings per share and valuation.

Regeneron Pharmaceuticals has higher revenue and earnings than Lexicon Pharmaceuticals. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Lexicon Pharmaceuticals and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Insider & Institutional Ownership

84.6% of Lexicon Pharmaceuticals shares are owned by institutional investors. Comparatively, 85.0% of Regeneron Pharmaceuticals shares are owned by institutional investors. 6.4% of Lexicon Pharmaceuticals shares are owned by insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Regeneron Pharmaceuticals beats Lexicon Pharmaceuticals on 13 of the 15 factors compared between the two stocks.

Lexicon Pharmaceuticals (NASDAQ:LXRX) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, dividends and valuation.

Insider & Institutional Ownership

84.6% of Lexicon Pharmaceuticals shares are owned by institutional investors. Comparatively, 83.5% of Biogen shares are owned by institutional investors. 6.4% of Lexicon Pharmaceuticals shares are owned by insiders. Comparatively, 0.5% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

Lexicon Pharmaceuticals has a beta of 2.09, indicating that its share price is 109% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.53, indicating that its share price is 47% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Lexicon Pharmaceuticals and Biogen, as provided by MarketBeat.com.

Lexicon Pharmaceuticals currently has a consensus price target of $9.40, suggesting a potential upside of 75.05%. Biogen has a consensus price target of $303.5517, suggesting a potential upside of 13.19%. Given Lexicon Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Lexicon Pharmaceuticals is more favorable than Biogen.

Earnings and Valuation

This table compares Lexicon Pharmaceuticals and Biogen's top-line revenue, earnings per share and valuation.

Biogen has higher revenue and earnings than Lexicon Pharmaceuticals. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Lexicon Pharmaceuticals and Biogen's net margins, return on equity and return on assets.

Summary

Biogen beats Lexicon Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Lexicon Pharmaceuticals (NASDAQ:LXRX) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership and earnings.

Insider and Institutional Ownership

84.6% of Lexicon Pharmaceuticals shares are held by institutional investors. Comparatively, 87.3% of Alexion Pharmaceuticals shares are held by institutional investors. 6.4% of Lexicon Pharmaceuticals shares are held by insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Lexicon Pharmaceuticals has a beta of 2.09, indicating that its stock price is 109% more volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, indicating that its stock price is 33% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations for Lexicon Pharmaceuticals and Alexion Pharmaceuticals, as provided by MarketBeat.

Lexicon Pharmaceuticals currently has a consensus price target of $9.40, suggesting a potential upside of 75.05%. Alexion Pharmaceuticals has a consensus price target of $153.8636, suggesting a potential downside of 0.74%. Given Lexicon Pharmaceuticals' higher possible upside, equities research analysts clearly believe Lexicon Pharmaceuticals is more favorable than Alexion Pharmaceuticals.

Earnings & Valuation

This table compares Lexicon Pharmaceuticals and Alexion Pharmaceuticals' top-line revenue, earnings per share and valuation.

Alexion Pharmaceuticals has higher revenue and earnings than Lexicon Pharmaceuticals. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Lexicon Pharmaceuticals and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Alexion Pharmaceuticals beats Lexicon Pharmaceuticals on 12 of the 15 factors compared between the two stocks.